New Alzheimer’s drug from Biogen and Eisai is just the beginning

A drug developed by Biogen Inc. and Eisai Co. has achieved a primary in Alzheimer’s analysis: In a big, late-stage trial, lecanemab slowed down the cognitive decline in individuals with early illness.

The remedy’s impact was modest. However given the litany of failures in Alzheimer’s drug growth, it’s a shocking flip for the sphere. And whereas skepticism in regards to the true which means of those outcomes — for sufferers, for the destiny of comparable medication, for our understanding of the illness — is warranted, the result’s significant sufficient to let the Alzheimer’s neighborhood have a good time a attainable win.